2. Immunology/Inflammation NF-κB Metabolic Enzyme/Protease Epigenetics PI3K/Akt/mTOR Apoptosis
  3. Interleukin Related Reactive Oxygen Species (ROS) AMPK FOXO COX Apoptosis
  4. Gypenoside A

Gypenoside A is an orally active triterpenoid compound that can be isolated from Gynostemma pentaphyllum. Gypenoside A has anti-inflammatory and antioxidant activities. Gypenoside A also has a certain protective effect on cardiomyocytes and can inhibit apoptosis. Gypenoside A can be used in the research of cardiovascular diseases and inflammation-related diseases.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Gypenoside A

Gypenoside A 構造式

CAS 番号 : 157752-01-7

容量 価格（税別） 在庫状況 数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 123 在庫あり
Solution
10 mM * 1 mL in DMSO USD 123 在庫あり
Solid
5 mg $62 在庫あり
10 mg $100 在庫あり
25 mg $160 在庫あり
50 mg   お問い合わせ  
100 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 1 publication(s) in Google Scholar

Gypenoside A 関連抗体

Top Publications Citing Use of Products

Interleukin Related アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

AMPK アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
NUAK1 NUAK2 AMPK AMPK α1β1γ1 AMPK α2β1γ1 AMPK α1β2γ1 AMPK α2β2γ1 BRSK1 BRSK2 HUNK AMPKα

FOXO アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
FOXO1 FOXO3

COX アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
COX COX-1 COX-2 COX-3

  • 生物活性

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー

製品説明

Gypenoside A is an orally active triterpenoid compound that can be isolated from Gynostemma pentaphyllum. Gypenoside A has anti-inflammatory and antioxidant activities. Gypenoside A also has a certain protective effect on cardiomyocytes and can inhibit apoptosis. Gypenoside A can be used in the research of cardiovascular diseases and inflammation-related diseases[1][2][3].

IC50 & Target[1][2]

FOXO1

 

IL-6

 

IL-13

 

IL-5

 

IL-4

 

体外実験

Gypenoside A (0-10 μM; 24 h) can reduce the secretion of cytokines and chemokines and inhibit the production of ROS in TNF-α/IL-4-treated BEAS-2B cells[1].
Gypenoside A (10-20 μM; 24 h) can increase cell viability and inhibit apoptosis in OGD/R-treated H9c2 cells. The mechanism involves the activation of the AMPK/Foxo1 signaling pathway and a decrease in the expression level of miR-143-3p[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Gypenoside A 関連抗体

Western Blot Analysis[2]

Cell Line: Oxygen-glucose deprivation/re-oxygenation (OGD/R) treated H9c2 cells
Concentration: 10 and 20 μM
Incubation Time: 24 h
Result: Restored the levels of p-AMPK and p-Foxo1.
体内実験

Gypenoside A (10-30 mg/kg; intraperitoneal injection; single dose) has an improving effect in a mouse asthma model[1].
Gypenoside A (100 mg/kg; gavage; single dose) can improve hemodynamic parameters, reduce apoptosis and infarct area in myocardial tissue in a rat myocardial ischemia/reperfusion injury model[2].
Pharmacokinetic Analysis in Rats[3]

Route Dose (mg/kg) AUC(0-t) (ng/mL·h) AUC(0-∞) (ng/mL·h) t1/2z (h) CLz/F (L/h/kg) Vz/F (L/kg) Cmax (ng/mL)
p.o. 5 14.9 15.9 1.4 319.9 665.4 8.6
i.v. 1 332.9 334.3 0.8 3.0 3.3 621.9

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female BALB/c mice aged 6 weeks old treated AlOH3 and 50 OVA[1]
Dosage: 10 and 30 mg/kg
Administration: Intraperitoneal injection; single dose
Result: Significantly reduced eosinophil infiltration in the lungs and tracheal goblet cell hyperplasia.
Mitigated airway hyperresponsiveness.
Decreased the levels of cytokines and chemokines in BALF, such as IL-4, IL-5, IL-13, TNF-α, IL-6, CCL11, and CCL24, while elevated IFN-γ levels.
Reduced OVA-IgE and OVA-IgG1 levels and increased OVA-IgG2a levels in serum.
Decreased IL-4, IL-5, and IL-13 levels and increased IFN-γ secretion in splenocytes.
Promoted GSH and suppressed MDA activity, and reduced TNF, IL6, and COX2 expression in the lungs.
分子量

899.07

分子式

C46H74O17
CAS 番号
Appearance

Solid

Color

White to off-white

SMILES

O=CC12C3C(C4(C(C(C5(CC(/C=C(C)/C)OC5O)O)CC4)CC3)C)(CCC1C(C)(C(OC6C(C(C(O)CO6)OC7C(C(C(O)CO7)O)O)OC8C(C(C(O)C(C)O8)O)O)CC2)C)C
Structure Classification
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶剤 & 溶解度
体外: 

DMSO : 100 mg/mL (111.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.1123 mL 5.5613 mL 11.1226 mL
5 mM 0.2225 mL 1.1123 mL 2.2245 mL
10 mM 0.1112 mL 0.5561 mL 1.1123 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始）

C1

×
体積 （開始）

V1

=
濃度 （終了）

C2

×
体積 （終了）

V2

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (2.78 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (2.78 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション

純度: 99.79%

COA (255 KB) HNMR (125 KB) RP-HPLC (212 KB) MS (159 KB)

取扱説明書 (2659 KB)
参考文献

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.1123 mL 5.5613 mL 11.1226 mL 27.8065 mL
5 mM 0.2225 mL 1.1123 mL 2.2245 mL 5.5613 mL
10 mM 0.1112 mL 0.5561 mL 1.1123 mL 2.7807 mL
15 mM 0.0742 mL 0.3708 mL 0.7415 mL 1.8538 mL
20 mM 0.0556 mL 0.2781 mL 0.5561 mL 1.3903 mL
25 mM 0.0445 mL 0.2225 mL 0.4449 mL 1.1123 mL
30 mM 0.0371 mL 0.1854 mL 0.3708 mL 0.9269 mL
40 mM 0.0278 mL 0.1390 mL 0.2781 mL 0.6952 mL
50 mM 0.0222 mL 0.1112 mL 0.2225 mL 0.5561 mL
60 mM 0.0185 mL 0.0927 mL 0.1854 mL 0.4634 mL
80 mM 0.0139 mL 0.0695 mL 0.1390 mL 0.3476 mL
100 mM 0.0111 mL 0.0556 mL 0.1112 mL 0.2781 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Gypenoside A Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量   濃度   体積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Gypenoside A157752-01-7Interleukin RelatedReactive Oxygen Species (ROS)AMPKFOXOCOXApoptosisILAMP-activated protein kinaseForkhead box OCyclooxygenaseasthma modelmyocardial ischemia/reperfusion injury modelBEAS-2B cellsH9c2 cellsInhibitorinhibitorinhibit

最近チェックした製品:

オンラインお問い合わせ

Your information is safe with us. * Required Fields.

製品名

  

カスタマ需要量 *

お名前 *

 

タイトル

メールアドレス *

 

電話番号 *

デパートメント

 

組纖名 *

市区町村

都道府県

国或いは地域 *

      

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
Gypenoside A
製品番号:
HY-N2440
数量:
MCE 日本正規代理店:

カスタマーレビュー

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

製品名

  

Lot #

お名前 *

 

メールアドレス *

電話番号 *

 

部門 *

組纖名 *

 

国或いは地域 *

備考

Request for HNMR Report

We have received your request and will respond to you as soon as possible.